Hepion Pharmaceuticals (HEPA) Prices 20M Share Common Offering at $1.50/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts annual forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
- S&P Global shares rise on report of possible CapIQ spinoff
Hepion Pharmaceuticals Prices Public Offering
November 24, 2020 7:25 PM ESTEDISON, NJ / ACCESSWIRE / November 24, 2020 / Hepion Pharmaceuticals, Inc. (NASDAQ: HEPA), a clinical stage biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis ("NASH"), today announced the pricing of an underwritten public offering of 20,000,000 shares of its common stock. Each share of common stock is being sold to the public at a price per share of $1.50. The gross proceeds to Hepion from this offering are expected to be approximately $30 million before deducting underwriting discounts, commissions and other offering expenses.
Hepion has... More
